Zeta CD163 Antibody. Zeta’s rabbit recombinant monoclonal antibody recognizes CD163, a protein of 140kDa. CD163 has been identified as an acute phase-regulated transmembrane protein whose function is to mediate the endocytosis of haptoglobin-hemoglobin complexes. The CD163 receptor is expressed on the surface of monocytes with low expression and on tissue macrophages, histiocytes with high expression. Staining with the antibody to CD163 has been helpful to distinguish synovial macrophages from synovial intimal fibroblasts in rheumatoid arthritis, where its specificity for macrophages was found to be superior to that of the antibody to CD68. Increased levels of CD163 were also detected in patients with microbial infections and myelomonocytic leukemias. The antibody to CD163 is of considerable value for selective identification of monocytes and macrophages at a certain stage of differentiation and is suitable for diagnosing myelomonocytic or monocytic leukaemia and neoplasms of true histiocytic origin. CD163 is positive in skin (histiocytes), gut, Kupffer cells, a few alveolar macrophages, macrophages in the placenta, and in macrophages in inflamed tissues including tumor tissue.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.